Ashvattha previews plans for long Covid trial in mid-2023
In the constantly evolving Covid-19 landscape, a lot can change in a short time. Two years after beginning a Phase IIa trial of OP-101 in…
Latest Deals
-
Florence HealthcareCapital Raising $27M
-
ImCheckCapital Raising $103M
-
CurebaseCapital Raising $40M
-
Panthera BiosciencesCapital Raising $13.04M
-
Florence HealthcareCapital Raising $27M
-
ImCheckCapital Raising $103M
-
CurebaseCapital Raising $40M
-
Panthera BiosciencesCapital Raising $13.04M
Deal Trends in the Pharma Industry
Deals Insights dashboard tracks deal trends in the pharma industry. The dashboard provides an extensive analysis by capturing trends in terms of deal types, geographies, industry players, advisory firms, and the number of deals and their value.
In partnership with
Deals database provides comprehensive coverage across industries tracking market activity of different transaction types.
Pharma industry deal activity by deal type - volume (Last 12 months)
The chart below provides an insightful and thorough overview of deal activity in terms of deal types and the number of deals in the global pharma industry over the last 12 months. It covers mergers and acquisitions (M&As), private equity and venture financing deal types.
Pharma industry deal activity by deal type - value (Last 12 months)
The deals insights dashboard offers an analysis on deal activity in the global pharma industry in terms of deal type and value. Deal types encompassing M&As, private equity and venture financing are tracked over the last 12 months.
Mergers and acquisitions in the pharma industry
The deals insights dashboard provides an overview of M&A deal activity in the pharma industry. Besides M&A deals, the dashboard tracks the leading M&A financial and legal advisors, and M&A deal activity by theme.
Pharma industry M&A deal activity by region (Last 12 months)
The map below shows the M&A transactions recorded in the pharma industry in different regions in the last 12-month period.
Largest M&A deals in the pharma industry
The following table lists details of the largest merger and acquisition deals in terms of value in the global pharma industry.
| Acquirer | Target | Deal Date | Value (US$m) |
|---|---|---|---|
| CSL | Vifor Pharma | 14 Dec 2021 | 12,300.0 |
| Pfizer | Biohaven Pharmaceutical Holding | 10 May 2022 | 12,210.5 |
| Merck | Acceleron Pharma | 29 Sep 2021 | 11,500.0 |
| Pfizer | Arena Pharmaceuticals | 13 Dec 2021 | 6,700.0 |
| Bristol-Myers Squibb | Turning Point Therapeutics | 03 Jun 2022 | 4,100.0 |
| Biocon Biologics | Viatris' Biosimilars Business | 27 Feb 2022 | 3,335.0 |
| GSK | Affinivax | 31 May 2022 | 3,300.0 |
| Novo Nordisk | Dicerna Pharmaceuticals | 18 Nov 2021 | 3,300.0 |
| Sanofi | Translate Bio | 03 Aug 2021 | 3,200.0 |
| Samsung Biologics | Samsung Bioepis | 27 Jan 2022 | 2,300.0 |
M&A deals advisor rankings in the pharma industry (2021 vs. 2020)
The deals insights dashboard reveals top financial and legal advisors to M&A deals by both deal value and volume in the global pharma industry during 2020 and 2021.
M&A financial advisor rankings in the pharma industry
The deals insights dashboard compares rankings of leading financial advisors to M&A transactions in terms of deal value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| The Goldman Sachs Group | 1 | 2 |
| Centerview Partners | 2 | 1 |
| J.P. Morgan Securities | 3 | 12 |
| Morgan Stanley | 4 | 4 |
| Bank of America | 5 | 3 |
| Barclays | 6 | 16 |
| Evercore | 7 | 6 |
| Guggenheim Partners | 8 | 10 |
| Credit Suisse Group | 9 | 14 |
| Citigroup | 10 | 13 |
The deals insights dashboard compares rankings of leading financial advisors to M&A transactions in terms of deal value and volume between 2020 and 2021, based on GlobalData’s Deals database.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| The Goldman Sachs Group | 1 | 1 |
| Centerview Partners | 2 | 2 |
| J.P. Morgan Securities | 3 | 19 |
| Morgan Stanley | 4 | 6 |
| Rothschild | 5 | 7 |
| SVB Financial Group | 6 | 31 |
| Jefferies | 7 | 4 |
| JPMorgan Chase | 8 | 8 |
| Cowen | 9 | 9 |
| Bank of America | 10 | 3 |
M&A legal advisor rankings in the pharma industry
The deals insights dashboard compares rankings of leading legal advisors to M&A transactions in terms of deal value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| Ropes & Gray | 1 | 15 |
| Simpson Thacher & Bartlett | 2 | 48 |
| Debevoise & Plimpton | 3 | 50 |
| Paul, Weiss, Rifkind, Wharton & Garrison | 4 | 20 |
| Kirkland & Ellis | 5 | 11 |
| Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates | 6 | 10 |
| Goodwin Procter | 7 | 3 |
| Cravath, Swaine & Moore | 8 | 9 |
| Fried, Frank, Harris, Shriver & Jacobson | 9 | 2 |
| Cooley | 10 | 13 |
The following table compares the rankings of leading legal advisors to M&A transactions in terms of deal value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| Goodwin Procter | 1 | 1 |
| Cooley | 2 | 2 |
| Latham & Watkins | 3 | 3 |
| White & Case | 4 | 6 |
| Ropes & Gray | 5 | 7 |
| Kirkland & Ellis | 6 | 10 |
| Jones Day | 7 | 14 |
| Wilson Sonsini Goodrich & Rosati | 8 | 5 |
| Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates | 9 | 8 |
| Baker & McKenzie | 10 | 16 |
M&A deal activity by theme in the pharma industry: Last 12 months (by volume)
The deals insights dashboard tracks the number of M&A deals by theme in the pharma industry based on GlobalData’s Deals database. The following chart lists top ten themes that hold the most number of deals.
Private equity deals in the pharma industry
The deals insights dashboard provides information on private equity deals data, including deals by region, top legal and financial advisors, and top deals by theme.
Private equity deal activity in the pharma industry by region (Last 12 months)
The map below shows the private equity deal activity in different regions of the globe over the last 12 months.
Top private equity deals in the pharma industry
The following table lists details of the largest private equity deals by value in the global pharma industry.
| Investor | Target | Deal Date | Value (US$m) |
|---|---|---|---|
| GIC | Swedish Orphan Biovitrum | 02 Sep 2021 | 8,047.6 |
| SD Biosensor | Meridian Bioscience | 07 Jul 2022 | 1,540.3 |
| CBC Group | Hugel | 27 Aug 2021 | 1,500.0 |
| Fidelity Management Research | EQRx | 06 Aug 2021 | 1,200.0 |
| FountainVest Partners | Beijing Zhendong Langdi Pharmaceutical | 19 Nov 2021 | 900.0 |
| Patient Square Capital | Radius Health | 23 Jun 2022 | 890.0 |
| D1 Capital Partners | Ultima Genomics | 31 May 2022 | 600.0 |
| BGH Capital | Virtus Health | 14 Dec 2021 | 519.1 |
| Aztiq Pharma Partners | Alvogen Emerging Markets Holdings | 09 May 2022 | 500.0 |
| Altaris Capital Partners | Johnson Matthey - Health business | 17 Dec 2021 | 432.1 |
Top private equity investors in the pharma industry (last 12 months)
The deals insights dashboard tracks top private equity investors in the pharma industry over the last 12 months.
| Investor Name | Value (US$m) | No of Deals |
|---|---|---|
| Bain Capital Life Sciences | 2,210.0 | 7 |
| BVF Partners | 1,539.1 | 5 |
| GEM Global Yield LLC SCS | 461.9 | 5 |
| RTW Investments | 366.4 | 5 |
| Great Point Partners | 125.0 | 5 |
| EcoR1 Capital | 316.6 | 4 |
| Lincoln Park Capital Fund | 150.0 | 4 |
| Armistice Capital Master Fund | 45.0 | 4 |
| ArchiMed | 34.8 | 4 |
| BroadOak Capital Partners | 20.0 | 4 |
Private equity deals advisors in the pharma industry (2021 vs. 2020)
The deals insights dashboard monitors financial and legal advisors to private equity deals by value and volume in the global pharma industry during 2020 and 2021.
Private equity financial advisor rankings in the pharma industry
The following table compares rankings of leading financial advisors to private equity transactions in terms of value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| Evercore | 1 | 8 |
| Morgan Stanley | 2 | 18 |
| Jefferies | 3 | 6 |
| The Goldman Sachs Group | 4 | 9 |
| Barclays | 5 | 16 |
| UBS Group | 6 | 45 |
| Rothschild | 7 | 1 |
| J.P. Morgan Securities | 8 | 37 |
| Lazard | 9 | 50 |
| Bank of America | 10 | 19 |
The deals insights dashboard compares ranking of leading financial advisors to private equity transactions in terms of value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| Jefferies | 1 | 1 |
| Rothschild | 2 | 5 |
| Cowen | 3 | 3 |
| SVB Financial Group | 4 | 2 |
| WBC Holdings | 5 | 10 |
| Morgan Stanley | 6 | 16 |
| J.P. Morgan Securities | 7 | 43 |
| Cantor Fitzgerald | 8 | 17 |
| The Goldman Sachs Group | 9 | 18 |
| Oppenheimer Holdings | 10 | 31 |
Private equity legal advisor rankings in the pharma industry
The deals insights dashboard compares ranking of leading legal advisors to private equity transactions in terms of value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| Uria Menendez Abogados SLP | 1 | 3 |
| Weil, Gotshal & Manges | 2 | 36 |
| Kirkland & Ellis | 3 | 25 |
| Linklaters | 4 | 7 |
| Latham & Watkins | 5 | 1 |
| Simpson Thacher & Bartlett | 6 | 12 |
| Sullivan & Cromwell | 7 | 50 |
| Mannheimer Swartling Advokatbyra | 8 | 38 |
| Ropes & Gray | 9 | 2 |
| Cleary Gottlieb Steen & Hamilton | 10 | 26 |
The deals insights dashboard compares ranking of leading legal advisors to private equity transactions in terms of value and volume between 2020 and 2021.
| Advisor Name | 2021 Rank | 2020 Rank |
|---|---|---|
| Goodwin Procter | 1 | 2 |
| Kirkland & Ellis | 2 | 4 |
| Ropes & Gray | 3 | 5 |
| Latham & Watkins | 4 | 1 |
| McDermott Will & Emery | 5 | 13 |
| Jones Day | 6 | 10 |
| White & Case | 7 | 20 |
| Cooley | 8 | 21 |
| Gibson, Dunn & Crutcher | 9 | 22 |
| Linklaters | 10 | 23 |
Private equity deals by theme in the pharma industry: Last 12 months (by volume)
The deals insights dashboard tracks the number of private equity deals by theme in the pharma industry based on GlobalData’s Deals database. The following chart lists top ten themes that hold the most number of deals in last 12 months.
Venture financing deals in the pharma industry
The deals insights dashboard provides an overview of venture financing deal activity in the pharma industry around the globe, including deals by region, top venture financing deals and capital investors.
Venture financing deal activity in the pharma industry by region (Last 12 months)
The deals insights dashboard tracks venture financing deals recorded in the pharma industry in different regions of the globe in the last 12-month period.
Top ten venture financing deals in the pharma industry
The following table lists the top ten venture financing deals by value in the global pharma industry.
| Investor | Target | Deal Date | Value (US$m) |
|---|---|---|---|
| Gaorong Capital | Suzhou Abogen Biosciences | 19 Aug 2021 | 700.0 |
| Undisclosed | National Resilience | 06 Jun 2022 | 625.0 |
| Undisclosed | National Resilience | 31 Aug 2021 | 600.0 |
| Schroders Capital | Eikon Therapeutics | 06 Jan 2022 | 517.8 |
| Scottish Enterprise | Kynos Therapeutics | 03 Feb 2022 | 506.6 |
| Canada Pension Plan Investment Board | Laronde | 30 Aug 2021 | 440.0 |
| Sino Biopharmaceutical | XtalPi | 11 Aug 2021 | 400.0 |
| Catalio Capital Management | Neumora Therapeutics | 07 Oct 2021 | 400.0 |
| Flagship Pioneering | Generate Biomedicines | 18 Nov 2021 | 370.0 |
| Maverick Capital | Areteia Therapeutics | 12 Jul 2022 | 350.0 |
Top venture capital investors in the pharma industry (Last 12 months)
The deals insights dashboard tracks top venture capital investors in the pharma industry over the last 12 months.
| Investor Name | Value (US$m) | No of Deals |
|---|---|---|
| RA Capital Management | 3,511.2 | 39 |
| Alexandria Venture Investments | 3,047.0 | 39 |
| Orbimed Advisors | 3,018.7 | 32 |
| Casdin Capital | 2,242.3 | 24 |
| Logos Global Management | 2,305.6 | 20 |
| ARCH Venture Partners | 3,059.7 | 19 |
| GV Management | 1,835.0 | 19 |
| Northpond Ventures | 1,249.2 | 19 |
| Lilly Asia ventures | 2,083.4 | 18 |
| Samsara BioCapital | 1,876.5 | 17 |
Venture financing deal activity by theme in the pharma industry: Last 12 months (by volume)
The chart below gives information about the number of venture financing deals by theme in the global pharma industry. The following chart lists top ten themes that hold the most number of deals in last 12 months.
All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Latest News
View More
Odyssey reports positive data from Phase I concussion trial
Odyssey Health has reported positive data from Cohort I of the multi-day ascending dosing (MAD) arm of the Phase I clinical trial analysing its new…
Gamida doses first subject in Phase I/II cell therapy trial for lymphomas
Gamida Cell has dosed the first subject in the Phase I/II clinical trial of natural killer (NK) cell therapy candidate…
Peel Therapeutics begins Phase I solid tumour trial
Peel Therapeutics has commenced a first-in-human Phase I clinical trial of its small molecule nanoparticle, PEEL-224, in advanced solid tumour…
MedStar and Georgetown scientists to conduct acute rhinosinusitis trial
MedStar Health has announced plans to conduct a clinical trial with Georgetown University scientists to analyse therapies and new data…
Upstream Bio doses first subject in Phase Ib asthma antibody trial
Upstream Bio has dosed the first subject in a Phase Ib multiple ascending dose clinical trial of monoclonal antibody, UPB-101, in patients…
Company A-Z
View More
GlobalData
GlobalData exists to help businesses decode the future to profit from faster, more informed decisions.
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
